Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | GMNN | O75496 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.75 |
| ▸ | TP53 | P04637 | 3/20 | 0.75 |
| ▸ | TSHR | P16473 | 3/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.75 |
| ▸ | BLM | P54132 | 2/20 | 0.75 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | GLA | P06280 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28289386 | 1.00 | CYP1A2 (0.77) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL22116262 | 1.00 | CYP1A2 (0.77) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL29440234 | 0.97 | CYP1A2 (0.82) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL22116167 | 0.97 | CYP1A2 (0.82) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL29652051 | 0.95 | MAPK1 (0.83) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL29378967 | 0.89 | MEN1 (0.72) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL31180037 | 0.89 | MEN1 (0.72) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL10626781 | 0.89 | MAPK1 (0.72) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL12137162 | 0.89 | CYP1A2 (0.91) | CYP1A2MAPK1LMNAMAPTMEN1 | |
| SCHEMBL28699690 | 0.89 | CYP1A2 (0.75) | CYP1A2MAPK1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390406-B2 | Process for treating keratin fibers using a composition comprising a carnitine salt or carnitine derivative salt comprising an aliphatic dicarboxylic acid anion | L'OREAL (FR) | 2025-08-19 | — | — | US | disclosed |
| CN-113194919-B | Method for treating keratin fibres using a composition comprising a carnitine salt or a carnitine derivative salt comprising an aliphatic dicarboxylic acid anion | 莱雅公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-115989409-A | Acyl carnitine analysis method and acyl carnitine analysis device | 株式会社岛津制作所 | 2023-04-18 | — | — | CN | disclosed |
| EP-3897559-B1 | PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN ALIPHATIC DICARBOXYLIC ACID ANION | OREAL (FR) | 2023-01-11 | — | — | EP | disclosed |
| US-20220062131-A1 | PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN ALIPHATIC DICARBOXYLIC ACID ANION | L'OREAL (FR) | 2022-03-03 | — | — | US | disclosed |
| EP-3897559-A1 | PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN ALIPHATIC DICARBOXYLIC ACID ANION | L'OREAL (FR) | 2021-10-27 | — | — | EP | disclosed |
| CN-113194919-A | Method for treating keratin fibres using a composition comprising a carnitine salt or a carnitine derivative salt containing an aliphatic dicarboxylic acid anion | 莱雅公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020127764-A1 | PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN ALIPHATIC DICARBOXYLIC ACID ANION | L'OREAL (FR) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390406-B2 | Process for treating keratin fibers using a composition comprising a carnitine salt or carnitine derivative salt comprising an aliphatic dicarboxylic acid anion | KRT18, CRAT, CPT1B | CYP1A2 4346/4885MAPK1 2275/4885LMNA 225/4885 |
| US-20220062131-A1 | PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN ALIPHATIC DICARBOXYLIC ACID ANION | KRT18, CRAT, CPT1B | CYP1A2 4346/4885MAPK1 2275/4885LMNA 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.